Novocure
Moshe Giladi currently serves as Novocure’s Chief Science Officer, where he oversees Novocure’s preclinical research organization and manages external research partnerships and Novocure’s biostatistics and data management teams. Mr. Giladi joined Novocure in 2005 and most recently held the title of Senior Vice President of Preclinical Research, overseeing a team dedicated to deepening understanding and driving acceptance of Tumor Treating Fields therapy. He holds a Ph.D. in Microbiology and Biochemistry and a master’s degree in business administration from Tel Aviv University.
This person is not in any offices
Novocure
3 followers
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma.